Tag Archives: Arch Therapeutics Inc

Arch Therapeutics Inc (ARTH) Gets a Buy Rating from Ladenburg

In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Arch Therapeutics Inc (ARTH – Research Report), with a price target of $1.25. The company’s shares closed yesterday at $0.28, close to its 52-week low of

H.C. Wainwright Sticks to Its Buy Rating for Arch Therapeutics Inc (ARTH)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Arch Therapeutics Inc (ARTH – Research Report) today and set a price target of $2.50. The company’s shares closed on Friday at $0.39. Selvaraju said: “Valuation methodology, risks and uncertainties.

Arch Therapeutics Inc Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Arch Therapeutics Inc (Other OTC: ARTH), with a price target of $3. The company’s shares closed yesterday at $0.50. Selvaraju said: “Valuation methodology, risks and

H.C. Wainwright Keeps Their Buy Rating on Arch Therapeutics Inc

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Arch Therapeutics Inc (Other OTC: ARTH), with a price target of $3. The company’s shares closed yesterday at $0.66. Selvaraju wrote: “We consider this a

Arch Therapeutics Inc Receives a Buy from Roth Capital

Roth Capital analyst Michael Higgins reiterated a Buy rating on Arch Therapeutics Inc (Other OTC: ARTH) today and set a price target of $3. The company’s shares opened today at $0.50. Higgins wrote: “We met this week with Arch’s CEO

Roth Capital Releases a Buy Rating on Arch Therapeutics Inc

In a report released yesterday, Michael Higgins from Roth Capital reiterated a Buy rating on Arch Therapeutics Inc (Other OTC: ARTH), with a price target of $3. The company’s shares opened today at $0.60. According to TipRanks.com, Higgins is ranked